MX367284B - Forma de medicamento para liberar los ingredientes activos. - Google Patents
Forma de medicamento para liberar los ingredientes activos.Info
- Publication number
- MX367284B MX367284B MX2014015660A MX2014015660A MX367284B MX 367284 B MX367284 B MX 367284B MX 2014015660 A MX2014015660 A MX 2014015660A MX 2014015660 A MX2014015660 A MX 2014015660A MX 367284 B MX367284 B MX 367284B
- Authority
- MX
- Mexico
- Prior art keywords
- medicament
- core
- active ingredient
- medicament form
- release
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 239000004480 active ingredient Substances 0.000 title abstract 4
- 210000004051 gastric juice Anatomy 0.000 abstract 2
- 230000002051 biphasic effect Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a la provisión de formas de medicamento que permiten la efectiva administración de un medicamento, que usualmente se toma dos veces al día o más diariamente por medio de una sola dosis diaria. Esto se logra de acuerdo con la invención mediante la provisión una forma de medicamento que comprende un centro, una capa intermedia resistente al jugo gástrico dispuesta en la superficie del centro, y una cubierta dispuesta en el lado opuesto de la capa intermedia desde el centro. Ambos, el centro y la cubierta comprenden una proporción de un ingrediente activo. El ingrediente activo se libera al menos una forma bifásica de la forma de medicamento, la primera fase relacionada con la liberación inmediata del ingrediente activo después de la ingestión en el jugo gástrico. La presente invención adicionalmente se refiere a un proceso para producir la forma de medicamento y a sus usos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012105528.9A DE102012105528A1 (de) | 2012-06-25 | 2012-06-25 | Arzneiform zur Freisetzung von Wirkstoffen |
| PCT/EP2013/063162 WO2014001267A2 (de) | 2012-06-25 | 2013-06-24 | Arzneiform zur freisetzung von wirkstoffen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014015660A MX2014015660A (es) | 2015-07-14 |
| MX367284B true MX367284B (es) | 2019-08-13 |
Family
ID=48656002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014015660A MX367284B (es) | 2012-06-25 | 2013-06-24 | Forma de medicamento para liberar los ingredientes activos. |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP2863896B1 (es) |
| AU (1) | AU2013283473B2 (es) |
| BR (1) | BR112014032578B1 (es) |
| CA (1) | CA2877190C (es) |
| CO (1) | CO7250447A2 (es) |
| DE (1) | DE102012105528A1 (es) |
| DK (1) | DK2679216T3 (es) |
| EA (1) | EA030871B1 (es) |
| ES (2) | ES2546172T3 (es) |
| HU (2) | HUE025739T2 (es) |
| IL (1) | IL236466B (es) |
| IN (1) | IN2014MN02526A (es) |
| MX (1) | MX367284B (es) |
| MY (1) | MY168531A (es) |
| PH (1) | PH12014502836A1 (es) |
| PL (2) | PL2679216T3 (es) |
| PT (2) | PT2863896T (es) |
| UA (1) | UA118836C2 (es) |
| WO (1) | WO2014001267A2 (es) |
| ZA (1) | ZA201409506B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| EP3431078B1 (en) | 2017-07-20 | 2021-01-20 | Intas Pharmaceuticals Limited | Non-pulsatile prolonged-release betahistine oral solid compositions |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| DE102018129419A1 (de) | 2018-11-22 | 2020-05-28 | Johannes Gutenberg-Universität Mainz | Acrylat-Copolymer für galenische Anwendungen |
| JP2025536556A (ja) | 2022-10-25 | 2025-11-07 | ヴェラダーミクス インコーポレイテッド | 放出調節ミノキシジル用組成物および使用方法 |
| DE102023002336A1 (de) * | 2023-06-09 | 2024-12-12 | euvorio GmbH | Kohlenhydrathaltige Zusammensetzungen in Drageeform |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503031A (en) * | 1982-12-17 | 1985-03-05 | Glassman Jacob A | Super-fast-starting-sustained release tablet |
| IT1229237B (it) * | 1989-05-08 | 1991-07-26 | Prodotti Formenti | Sali di (2-(piridil)etil) metilammina |
| ES2051658T3 (es) * | 1992-08-06 | 1998-06-16 | Gergely Gerhard | Comprimidos efervescentes faciles de administrar. |
| HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
| US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| IT1309591B1 (it) | 1999-03-05 | 2002-01-24 | Formenti Farmaceutici Spa | Composizioni a rilascio controllato di betaistina. |
| DE10010509A1 (de) | 2000-03-08 | 2001-09-13 | Dresden Arzneimittel | Pharmazeutische Formulierungen |
| DE10104880A1 (de) | 2001-01-31 | 2002-08-08 | Roehm Gmbh | Multipartikuläre Arzneiform, enthaltend mindestens zwei unterschiedlich überzogene Pelletformen |
| DE60320965D1 (de) * | 2003-07-04 | 2008-06-26 | Formenti Farmaceutici Spa | Betahistinezubereitungen mit kontrollierter Freisetzung |
| US20060280795A1 (en) * | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
| EP2061440A2 (en) * | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| US20130323309A1 (en) * | 2011-02-17 | 2013-12-05 | Lupin Limited | Sustained Release Composition of Memantine |
-
2012
- 2012-06-25 DE DE102012105528.9A patent/DE102012105528A1/de not_active Ceased
-
2013
- 2013-06-24 PL PL13173438T patent/PL2679216T3/pl unknown
- 2013-06-24 EP EP13730597.5A patent/EP2863896B1/de active Active
- 2013-06-24 EA EA201500044A patent/EA030871B1/ru unknown
- 2013-06-24 HU HUE13173438A patent/HUE025739T2/en unknown
- 2013-06-24 MX MX2014015660A patent/MX367284B/es active IP Right Grant
- 2013-06-24 IN IN2526MUN2014 patent/IN2014MN02526A/en unknown
- 2013-06-24 PT PT137305975T patent/PT2863896T/pt unknown
- 2013-06-24 UA UAA201500502A patent/UA118836C2/uk unknown
- 2013-06-24 BR BR112014032578-2A patent/BR112014032578B1/pt active IP Right Grant
- 2013-06-24 MY MYPI2014003551A patent/MY168531A/en unknown
- 2013-06-24 PL PL13730597T patent/PL2863896T3/pl unknown
- 2013-06-24 CA CA2877190A patent/CA2877190C/en active Active
- 2013-06-24 AU AU2013283473A patent/AU2013283473B2/en active Active
- 2013-06-24 PT PT131734386T patent/PT2679216E/pt unknown
- 2013-06-24 WO PCT/EP2013/063162 patent/WO2014001267A2/de not_active Ceased
- 2013-06-24 DK DK13173438.6T patent/DK2679216T3/en active
- 2013-06-24 HU HUE13730597A patent/HUE031246T2/en unknown
- 2013-06-24 EP EP13173438.6A patent/EP2679216B1/de active Active
- 2013-06-24 ES ES13173438.6T patent/ES2546172T3/es active Active
- 2013-06-24 ES ES13730597.5T patent/ES2607447T3/es active Active
-
2014
- 2014-12-19 PH PH12014502836A patent/PH12014502836A1/en unknown
- 2014-12-23 ZA ZA2014/09506A patent/ZA201409506B/en unknown
- 2014-12-25 IL IL236466A patent/IL236466B/en active IP Right Grant
-
2015
- 2015-01-15 CO CO15007542A patent/CO7250447A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502836B1 (en) | Medicament form for release of active ingredients | |
| MX2015006613A (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| WO2012131463A3 (en) | Controlled release pharmaceutical dosage forms | |
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| WO2011076749A3 (en) | Solid pharmaceutical dosage form of ticagrelor | |
| CL2014002935A1 (es) | Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador | |
| JP2014515038A5 (es) | ||
| WO2011159100A3 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| PH12020550806A1 (en) | Core tablet composite preparation comprising mosapride and rabeprazole | |
| PH12014501408A1 (en) | Immediate release multi unit pellet system | |
| HK1223825A1 (zh) | 包含阿曲生坦的稳定化药物剂型 | |
| PH12015500653A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| MD4563B1 (ro) | Produs de comicronizare cu conţinut de acetat de ulipristal | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| PH12013500980A1 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| NZ613264A (en) | Use of vitamin k for weight maintenance and weight control | |
| JP2013079218A5 (es) | ||
| IN2012CH05549A (es) | ||
| TH104149B (th) | รูปแบบยาเวชภัณฑ์สำหรับการปลดปล่อยส่วนประกอบออกฤทธิ์ (Medicament form for release of active ingredients) | |
| WO2014170820A3 (en) | A pharmaceutical combination for treating tuberculosis | |
| WO2012033348A3 (ko) | 2-리놀레오일 글리세롤을 포함하는 알러지성 질환의 예방 또는 치료용 조성물 | |
| TN2013000212A1 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and mathod for the preparation therof | |
| PH22011000489U3 (en) | Solid pharmaceutical herbal compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |